A5060471170- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Systemic Lupus Erythematosus Research
- Psoriasis: Treatment and Pathogenesis
- Biosimilars and Bioanalytical Methods
- Musculoskeletal synovial abnormalities and treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Orthopedic Infections and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Musculoskeletal Disorders and Rehabilitation
- Autoimmune Bullous Skin Diseases
- Hematological disorders and diagnostics
- Bone and Joint Diseases
- Immunodeficiency and Autoimmune Disorders
- Hepatitis C virus research
- Medical and Health Sciences Research
- Vasculitis and related conditions
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Tuberculosis Research and Epidemiology
- Adolescent and Pediatric Healthcare
- Chronic Myeloid Leukemia Treatments
- Health and Medical Studies
Fachklinik 360°
2015-2024
Praxis
2013
Evangelisches Diakoniekrankenhaus
2007-2008
Abstract Objective To investigate the efficacy and tolerability of infliximab therapy for articular dermatologic manifestations active psoriatic arthritis (PsA). Methods One hundred four patients with PsA in whom prior at least 1 disease‐modifying antirheumatic drug (DMARD) had failed were recruited into this investigator‐initiated, multicenter, randomized, double‐blind, placebo‐controlled clinical trial. During initial blinded portion study, received infusions (5 mg/kg) or placebo weeks 0,...
Abstract Objective To assess the effect of 5 mg/day prednisolone on disease progression in patients with early rheumatoid arthritis (RA) receiving standardized disease‐modifying antirheumatic drug (DMARD) therapy. Methods Patients active RA <2 years' duration were randomly assigned a double‐blinded manner to receive or placebo while starting concomitant DMARD therapy (gold sodium thiomalate methotrexate). Hand and foot radiographs taken at baseline 6, 12, 24 months evaluated according...
Abstract Objective Randomized clinical trials (RCTs) evaluate the efficacy of treatments in selected groups patients defined by strict inclusion criteria. The value these predicting therapeutic effectiveness “real world” is limited. This observational cohort study was designed to complement knowledge obtained RCTs evaluating tumor necrosis factor (TNF) inhibitors with rheumatoid arthritis (RA) according their eligibility for major trials. Methods Using data from German biologics register...
Abstract Introduction Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective this study was evaluate the safety and clinical outcomes in several standard-of-care-refractory (within rheumatology, nephrology, dermatology neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma real-life setting. Methods Patients received having shown an inadequate...
Abstract Objective To determine the hazard risk of developing or worsening heart failure in rheumatoid arthritis (RA) patients treated with tumor necrosis factor α (TNFα) inhibitors. Methods RA ages 18–75 years who started treatment infliximab, etanercept, adalimumab (n = 2,757), conventional disease‐modifying antirheumatic drugs (controls; n 1,491) at time enrollment a German biologics register were studied. Cox proportional hazards models applied to investigate influence disease‐related...
To investigate the long-term effects of induction therapy with adalimumab (ADA) plus methotrexate (MTX) in comparison placebo (PBO) MTX DMARD-naïve patients active early rheumatoid arthritis (RA).Patients RA (disease duration ≤12 months) were randomly assigned to receive 40 mg ADA subcutaneously every other week (eow) 15 mg/week or PBO at over 24 weeks. Thereafter, all received monotherapy up 48. The primary outcome was Disease Activity Score 28 (DAS28) Secondary outcomes included...
<h3>Background</h3> New strategies and options for the treatment of rheumatoid arthritis (RA) have evolved during past decade. A study was undertaken to investigate what extent this influenced daily rheumatological care how translates into clinical patient-reported outcomes. <h3>Methods</h3> Data from a total 38 723 outpatients with RA enrolled in National Database German Collaborative Arthritis Centres years 1997–2007 were analysed. The cross-sectional annual data compared detect time...
The aim of this study was to evaluate the safety and efficacy rituximab (RTX) in a large cohort patients with rheumatoid arthritis routine care, monitor changes daily practice since introduction RTX therapy. This multicentre, prospective, non-interventional conducted under conditions Germany. Efficacy evaluated using Disease Activity Score 28 joints (DAS28) Health Assessment Questionnaire-Disability Index (HAQ-DI). Safety assessed by recording adverse drug reactions (ADRs). Physician patient...
Hand osteoarthritis (OA) is a condition characterised by cartilage degradation and frequently erosive changes. Analgesics non-steroidal anti-inflammatory drugs are used for symptomatic relief but often poorly tolerated or contraindicated. Previous publications suggest hydroxychloroquine (HCQ) as possible treatment hand OA. The OA-TREAT study aimed to investigate the efficacy safety of HCQ in patients with inflammatory OA (EOA).OA-TREAT was an investigator-initiated, multicentre, randomised,...
Abstract Objective To assess the effect of rituximab plus methotrexate (MTX) compared with MTX alone on patient‐reported outcomes (PROs) and health‐related quality life (HRQOL) in patients active early rheumatoid arthritis (RA) previously untreated MTX. Methods Patients RA were randomized to groups receiving placebo, 500 mg, or 1,000 mg. Rituximab was given by intravenous infusion days 1 15. From week 24, a Disease Activity Score 28 joints–erythrocyte sedimentation rate ≥2.6 eligible for...
The objective of this study was to use data from a noninterventional evaluate the effectiveness adalimumab in rheumatoid arthritis (RA) patients during routine clinical practice and explore potential impact patient disease characteristics response therapy. A total 2,625 RA with specified at baseline (prior initiating treatment) 12 months entered between April 2003 March 2009. We evaluated therapy conducted stepwise regression subgroup analyses factors influencing therapeutic response. During...
Tocilizumab (TCZ) and tumour necrosis factor inhibitors (TNFi) are recommended for the treatment of rheumatoid arthritis (RA) in patients with inadequate response (IR) to prior disease-modifying antirheumatic drugs (DMARDs). This retrospective analysis assessed efficacy TCZ TNFi, alone or combination DMARDs, 1603 IR previous either DMARDs (DMARD-IR) and/or TNFi (TNFi-IR), initiating a managed routine clinical practice. Patients were grouped according history initiated: DMARD-IR + DMARD...
The Non Interventional Evaluation with Golumimab (GO-NICE) study aimed to document patient and treatment characteristics as well clinical effectiveness safety in adult patients newly treated the tumour necrosis factor inhibitor golimumab (GLM).Prospective non-interventional 24-month observation per patient.158 office-based clinical-based physicians Germany.GLM administered 50 mg dose subcutaneously monthly intervals under real-life conditions.Of 1613 included patients, 1458 were eligible for...
Felty's syndrome is a rare disorder characterized as systemic manifestation of severe rheumatoid arthritis associated with granulocytopenia and splenomegaly. We report retrospective analysis series seven patients treated successfully low-dose methotrexate. leading to sustained clinical improvement (number swollen joints) normalization the granulocyte count for an observation period 1 yr. Our cohort largest ever published methotrexate treatment this condition. results confirm earlier single...